Xenetic Biosciences Future Growth
Future criteria checks 2/6
Xenetic Biosciences's earnings are forecast to decline at 34.4% per annum while its annual revenue is expected to grow at 35.9% per year. EPS is expected to grow by 25.8% per annum.
Key information
-34.4%
Earnings growth rate
25.8%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 35.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -15 | N/A | N/A | 1 |
| 12/31/2025 | 2 | -9 | N/A | N/A | 1 |
| 12/31/2024 | 2 | -6 | N/A | N/A | 1 |
| 9/30/2024 | 3 | -4 | -3 | -3 | N/A |
| 6/30/2024 | 3 | -5 | -3 | -3 | N/A |
| 3/31/2024 | 2 | -4 | -4 | -4 | N/A |
| 12/31/2023 | 3 | -4 | -4 | -4 | N/A |
| 9/30/2023 | 2 | -4 | -4 | -4 | N/A |
| 6/30/2023 | 2 | -4 | -4 | -4 | N/A |
| 3/31/2023 | 2 | -6 | -4 | -4 | N/A |
| 12/31/2022 | 2 | -7 | -5 | -5 | N/A |
| 9/30/2022 | 2 | -7 | -6 | -5 | N/A |
| 6/30/2022 | 1 | -7 | -6 | -5 | N/A |
| 3/31/2022 | 1 | -6 | -5 | -5 | N/A |
| 12/31/2021 | 1 | -6 | -5 | -5 | N/A |
| 9/30/2021 | 1 | -5 | -4 | -4 | N/A |
| 6/30/2021 | 1 | -11 | -4 | -4 | N/A |
| 3/31/2021 | 1 | -11 | -5 | -5 | N/A |
| 12/31/2020 | 0 | -11 | -4 | -4 | N/A |
| 9/30/2020 | 0 | -11 | -5 | -5 | N/A |
| 6/30/2020 | 0 | -14 | -6 | -6 | N/A |
| 3/31/2020 | 0 | -14 | -6 | -6 | N/A |
| 12/31/2019 | 0 | -18 | -6 | -6 | N/A |
| 9/30/2019 | N/A | -19 | -6 | -6 | N/A |
| 6/30/2019 | N/A | -10 | -5 | -5 | N/A |
| 3/31/2019 | N/A | -11 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -7 | -6 | -6 | N/A |
| 9/30/2018 | 8 | -1 | -1 | -1 | N/A |
| 6/30/2018 | 8 | -2 | N/A | -1 | N/A |
| 3/31/2018 | 8 | -3 | N/A | 0 | N/A |
| 12/31/2017 | 8 | -4 | N/A | 1 | N/A |
| 9/30/2017 | 3 | -12 | N/A | -8 | N/A |
| 6/30/2017 | 3 | -13 | N/A | -7 | N/A |
| 3/31/2017 | 3 | -58 | N/A | -7 | N/A |
| 12/31/2016 | 3 | -58 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -57 | N/A | -5 | N/A |
| 6/30/2016 | N/A | -60 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -13 | N/A | -5 | N/A |
| 9/30/2015 | N/A | -13 | N/A | -7 | N/A |
| 6/30/2015 | N/A | -11 | N/A | -8 | N/A |
| 3/31/2015 | N/A | -13 | N/A | -11 | N/A |
| 12/31/2014 | N/A | -14 | N/A | -13 | N/A |
| 9/30/2014 | N/A | -14 | N/A | -12 | N/A |
| 6/30/2014 | N/A | -13 | N/A | -12 | N/A |
| 3/31/2014 | 1 | -11 | N/A | -9 | N/A |
| 12/31/2013 | 1 | -9 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XBIO's revenue (35.9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: XBIO's revenue (35.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XBIO's Return on Equity is forecast to be high in 3 years time